BACKGROUND: Prognostic biomarkers for osteosarcoma (OS) at the time of diagnosis are lacking. Necrotic response of OS to preoperative chemotherapy correlates with survival and is determined 3-4 months after diagnosis. The purpose of this study is to identify biomarkers that will stratify patients into good or poor responders to chemotherapy at diagnosis and determine the role of potential biomarkers in OS pathogenesis. PROCEDURE: Because OS may be caused by disruptions of osteogenic differentiation, and the Notch pathway is one regulator of bone development, we examined the link between Notch effectors, OS differentiation, and OS outcome. We probed the R2: Genomics Analysis and Visualization Platform for RNA expression levels of Notch targets in mixed high-grade OS pretreatment biopsies. We used human OS cell lines in vitro and in mice to determine the role of the Notch target hairy/enhancer of split 4 (Hes4) in OS. RESULTS: We found that in OS patients, high expression of Hes4 is correlated with decreased metastasis-free and overall survival. Human OS cells that overexpress Hes4 are more immature and have an increased invasive capacity in vitro. This was not universal to all Notch effectors, as Hes1 overexpression induced opposing effects. When injected into NSG mice, Hes4-overexpressing OS cells produced significantly larger, more lytic tumors and significantly more metastases than did control cells. CONCLUSIONS: Hes4 overexpression promotes a more aggressive tumor phenotype by preventing osteoblastic differentiation of OS cells. Hes4 expression may allow for the stratification of patients into good or poor responders to chemotherapy at diagnosis.
BACKGROUND: Prognostic biomarkers for osteosarcoma (OS) at the time of diagnosis are lacking. Necrotic response of OS to preoperative chemotherapy correlates with survival and is determined 3-4 months after diagnosis. The purpose of this study is to identify biomarkers that will stratify patients into good or poor responders to chemotherapy at diagnosis and determine the role of potential biomarkers in OS pathogenesis. PROCEDURE: Because OS may be caused by disruptions of osteogenic differentiation, and the Notch pathway is one regulator of bone development, we examined the link between Notch effectors, OS differentiation, and OS outcome. We probed the R2: Genomics Analysis and Visualization Platform for RNA expression levels of Notch targets in mixed high-grade OS pretreatment biopsies. We used human OS cell lines in vitro and in mice to determine the role of the Notch target hairy/enhancer of split 4 (Hes4) in OS. RESULTS: We found that in OS patients, high expression of Hes4 is correlated with decreased metastasis-free and overall survival. Human OS cells that overexpress Hes4 are more immature and have an increased invasive capacity in vitro. This was not universal to all Notch effectors, as Hes1 overexpression induced opposing effects. When injected into NSG mice, Hes4-overexpressing OS cells produced significantly larger, more lytic tumors and significantly more metastases than did control cells. CONCLUSIONS:Hes4 overexpression promotes a more aggressive tumor phenotype by preventing osteoblastic differentiation of OS cells. Hes4 expression may allow for the stratification of patients into good or poor responders to chemotherapy at diagnosis.
Authors: Zhong-Liang Deng; Katie A Sharff; Ni Tang; Wen-Xin Song; Jinyong Luo; Xiaoji Luo; Jin Chen; Erwin Bennett; Russell Reid; David Manning; Anita Xue; Anthony G Montag; Hue H Luu; Rex C Haydon; Tong-Chuan He Journal: Front Biosci Date: 2008-01-01
Authors: Alexander Stoeck; Serguei Lejnine; Andrew Truong; Li Pan; Hongfang Wang; Chongzhi Zang; Jing Yuan; Chris Ware; John MacLean; Philip W Garrett-Engele; Michael Kluk; Jason Laskey; Brian B Haines; Christopher Moskaluk; Leigh Zawel; Stephen Fawell; Gary Gilliland; Theresa Zhang; Brandon E Kremer; Birgit Knoechel; Bradley E Bernstein; Warren S Pear; X Shirley Liu; Jon C Aster; Sriram Sathyanarayanan Journal: Cancer Discov Date: 2014-08-07 Impact factor: 39.397
Authors: Deanna D Dailey; Kristin P Anfinsen; Liza E Pfaff; E J Ehrhart; J Brad Charles; Tina B Bønsdorff; Douglas H Thamm; Barbara E Powers; Thora J Jonasdottir; Dawn L Duval Journal: BMC Vet Res Date: 2013-07-01 Impact factor: 2.741
Authors: Siobhan Simpson; Mark David Dunning; Simone de Brot; Llorenç Grau-Roma; Nigel Patrick Mongan; Catrin Sian Rutland Journal: Acta Vet Scand Date: 2017-10-24 Impact factor: 1.695
Authors: Li Yieng Lau; Loan T Nguyen; Antonio Reverter; Stephen S Moore; Aaron Lynn; Liam McBride-Kelly; Louis Phillips-Rose; Mackenzie Plath; Rhys Macfarlane; Vanisha Vasudivan; Lachlan Morton; Ryan Ardley; Yunan Ye; Marina R S Fortes Journal: Vet Med Sci Date: 2020-05-20
Authors: Karen Davey; Daniel Wong; Filip Konopacki; Eugene Kwa; Tony Ly; Heike Fiegler; Christopher R Sibley Journal: Sci Rep Date: 2021-04-12 Impact factor: 4.379